<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792115</url>
  </required_header>
  <id_info>
    <org_study_id>130002</org_study_id>
    <secondary_id>13-DK-0002</secondary_id>
    <nct_id>NCT01792115</nct_id>
  </id_info>
  <brief_title>Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E</brief_title>
  <official_title>Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Non-alcoholic fatty liver disease (NAFLD) is an excess accumulation of fat in the liver&#xD;
           cells. It is associated with obesity, high blood pressure, high cholesterol, and&#xD;
           diabetes. Some people with NAFLD only have excess fat in the liver. However, other&#xD;
           people may develop a worse form of NAFLD with liver injury and scarring. This form,&#xD;
           called non-alcoholic steatohepatitis (NASH), can lead to liver failure, liver cancer,&#xD;
           and death. Not much is known about why some people develop NASH and others do not.&#xD;
&#xD;
        -  Lifestyle changes such as diet, exercise, and weight loss can decrease the liver damage&#xD;
           in NAFLD. Some studies show that vitamin E can also help treat NAFLD. The dose of&#xD;
           vitamin E used in these studies is almost 40 times the recommended amount of vitamin E&#xD;
           intake from food. It is unclear whether a lower dose could achieve the same effect.&#xD;
           Researchers also want to study how vitamin E works at different doses to treat NAFLD.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To find out the most effective dose of vitamin E to treat NAFLD.&#xD;
&#xD;
        -  To gain a better understanding of how NAFLD and NASH develop, and predict who will&#xD;
           respond to treatment.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals at least 18 years of age with suggestion of non-alcoholic fatty liver disease.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history. Blood and urine&#xD;
           samples will be collected.&#xD;
&#xD;
        -  For the first 12 weeks of the study, participants will meet with a nutritionist. They&#xD;
           will have personalized diet and exercise plans. Treatment will be monitored with diaries&#xD;
           and questionnaires to fill out at home. Participants will also wear a pedometer to&#xD;
           measure physical activity.&#xD;
&#xD;
        -  After the 12-week period, participants will have a full physical examination with the&#xD;
           following tests:&#xD;
&#xD;
        -  Blood tests&#xD;
&#xD;
        -  Glucose tolerance tests&#xD;
&#xD;
        -  Imaging studies (DEXA scan and magnetic resonance imaging)&#xD;
&#xD;
        -  Liver and fatty tissue biopsy&#xD;
&#xD;
        -  Two weeks after the tests, participants will start vitamin E treatment. They will take&#xD;
           up to two pills a day, taken with fat-containing foods.&#xD;
&#xD;
        -  4 weeks after starting treatment they will have a repeat full evaluation with imaging&#xD;
           tests, blood work, and liver and fat biopsies.&#xD;
&#xD;
        -  Participants who are taking vitamin E will take it for up to 120 weeks. They will have&#xD;
           monitoring visits every 8 to 12 weeks. At the end of 120 weeks, they will have another&#xD;
           full evaluation, with imaging tests, blood work, and liver and fat biopsies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is the most common cause for liver test&#xD;
      abnormalities in the western world, and an increasingly rising cause for liver-related&#xD;
      morbidity and mortality. Vitamin E, a fat-soluble anti-oxidant was recently found to be an&#xD;
      effective treatment for NAFLD; however, its mechanism of action is unclear. In a controlled&#xD;
      clinical trial vitamin E treatment was shown to significantly reduce the hepatic fat burden,&#xD;
      suggesting mechanisms other than reducing oxidative stress are involved. Furthermore, the&#xD;
      optimal dose of vitamin E to treat NAFLD is unknown.&#xD;
&#xD;
      We propose a phase IIa study to determine the optimal dose of vitamin E and its mechanism and&#xD;
      site of action. In this study we aim to enroll up to 90 patients with NAFLD. Initially, all&#xD;
      patients will undergo 12 weeks of intensive lifestyle modification. Following that, all&#xD;
      patients will be randomized to treatment with 3 different doses of natural vitamin E (rrr-&#xD;
      -tocopherol at 200, 400 or 800 IU/d) for 24 weeks. The primary end points for efficacy are&#xD;
      normalization of liver enzymes and reduction in liver fat contents by magnetic resonance&#xD;
      spectroscopy. Patients will undergo liver and adipose tissue biopsies before vitamin E&#xD;
      treatment and after 4 weeks of therapy, and the biopsy samples will be used to measure&#xD;
      changes in gene expression and markers of oxidative stress. This will be coupled with&#xD;
      extensive phenotyping before and after treatment using serological, radiological and dynamic&#xD;
      endocrine testing and is aimed at finding the dose-response characteristics of vitamin E in&#xD;
      NAFLD, and allowing us to understand the mechanism of its action.&#xD;
&#xD;
      After 24 weeks of randomized treatment, all patients will be switched to a dose of 800 IU/ml&#xD;
      and will continue treatment for up to 30 months, at the end of which another liver biopsy&#xD;
      will be performed. From this phase we will assess the effects of dose increase of vitamin E&#xD;
      on liver enzymes and fat content, and will determine the effect of long-term treatment on&#xD;
      histological outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2013</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical: Number of Patients With Normal Transaminases at End of Treatment.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Biochemical response defined as number of patients with normal transaminases AST &lt;=32 or ALT &lt;=35 U/L at end of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiological: Absolute Change in Liver Fat</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Physiological response defined as absolute change in liver fat measured by 1H-MRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in AST</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Absolute Change in AST [u/l] by week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in AST</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Percent change in AST by week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in ALT</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Absolute Change in ALT [u/l] by week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in ALT</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Percent change in ALT by week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in GGT</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change in GGT by week 24 (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Liver Fat</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Percent change in liver fat by week 24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Vit E 200 IU/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E 400</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E 800</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E 200 IU/d</intervention_name>
    <description>Supplement-low dose</description>
    <arm_group_label>Vit E 200 IU/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E 400 IU/d</intervention_name>
    <description>Supplement-intermediate dose</description>
    <arm_group_label>Vitamin E 400</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E 800 IU/d</intervention_name>
    <description>Supplement High Dose</description>
    <arm_group_label>Vitamin E 800</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet and Exercise</intervention_name>
    <description>Diet and Exercise for all Arms of the study at baseline</description>
    <arm_group_label>Vit E 200 IU/d</arm_group_label>
    <arm_group_label>Vitamin E 400</arm_group_label>
    <arm_group_label>Vitamin E 800</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Clinical suspicion of NAFLD, defined by the presence of at least two of the following&#xD;
        criteria:&#xD;
&#xD;
          -  Suggestion of liver fat by an imaging study (ultrasound, CT scan, MRI or MR&#xD;
             spectroscopy) performed in the 6 months prior to enrollment.&#xD;
&#xD;
          -  Elevated aminotransferase levels (ALT &gt; 31 U/L for men or &gt; 19 U/L for women, or AST &gt;&#xD;
             30 U/L) on at least two occasions in the 6 months preceding enrollment.&#xD;
&#xD;
          -  Presence of the metabolic syndrome, defined according to the modified AHA/NCEP&#xD;
             criteria as the presence of at least three of:&#xD;
&#xD;
               -  Abdominal obesity, defined as waist circumference &gt; 102 cm for men or &gt; 88 cm for&#xD;
                  women&#xD;
&#xD;
               -  Elevated triglycerides (&gt; 150 mg/dL) or the use of medication to lower&#xD;
                  triglycerides&#xD;
&#xD;
               -  Reduced HDL cholesterol (&lt; 40 mg/DL for men or &lt; 50 mg/dL for women)&#xD;
&#xD;
               -  Elevated blood pressure (&gt; 135/80 mmHg) or use of medication for hypertension&#xD;
&#xD;
               -  Elevated fasting glucose levels (&gt; 100 mg/dL) or use of anti-diabetic medication&#xD;
&#xD;
                    -  For the purpose of inclusion, the presence of overt diabetes mellitus type 2&#xD;
                       will be considered equivalent to the presence of the metabolic syndrome,&#xD;
                       even if the other criteria are absent.&#xD;
&#xD;
          -  Estimated average alcohol consumption &lt; 30 g/d for men or &lt; 20 g/d for women in the 6&#xD;
             months prior to enrollment and no binge-drinking behavior.&#xD;
&#xD;
          -  Age &gt; 18 years at enrollment&#xD;
&#xD;
          -  Willingness to participate in the study&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV). Patients&#xD;
             who were treated successfully for HCV and achieved sustained virological response can&#xD;
             be eligible for enrollment &gt; 18 months after treatment cessation. Patients who are&#xD;
             inactive carriers of HBV (HBV DNA &lt; 1000 copies/mL, HBeAg negative, Anti HDV negative)&#xD;
             for at least 12 months prior to enrollment are also eligible. Patients receiving&#xD;
             antiviral therapy are ineligible.&#xD;
&#xD;
          -  Concomitant liver disease such as autoimmune hepatitis, primary biliary cirrhosis,&#xD;
             primary sclerosing cholangitis, Wilson s disease, alpha-1 antitrypsin deficiency.&#xD;
&#xD;
          -  Presence of definite or probable drug-induced liver injury. In the case of&#xD;
             lipid-lowering, anti-hypertensive or anti-diabetic medications that are suspected to&#xD;
             cause elevation of aminotransferases, patients will be eligible if treatment is&#xD;
             associated with stable enzyme levels for at least 6 months and inclusion criteria 1a.&#xD;
             and 1c. are both present.&#xD;
&#xD;
          -  Treatment with medications known to cause fatty liver disease such as atypical&#xD;
             neuroleptics, tetracycline, methotrexate or tamoxifen&#xD;
&#xD;
          -  Uncontrolled hypo- or hyperthyroidism.&#xD;
&#xD;
          -  Decompensated advanced liver disease, defined as direct bilirubin &gt; 0.5 g/dL, PT &gt; 18,&#xD;
             albumin &lt; 3 g/dL, or history of ascites, encephalopathy, variceal bleeding,&#xD;
             spontaneous bacterial peritonitis or liver transplant.&#xD;
&#xD;
          -  Active coronary artery disease, defined as persistent angina pectoris, reversible&#xD;
             ischemia on cardiac stress test or imaging, or the presence of significant coronary&#xD;
             artery disease on imaging or catheterization. Patients with coronary artery disease&#xD;
             that was treated by angioplasty or bypass surgery may be eligible if they have no&#xD;
             evidence of active disease &gt;= 1 year after intervention, can safely stop antiplatelet&#xD;
             and anticoagulant medications before the performance of invasive procedures, and have&#xD;
             adequate ventricular function as assessed by echocardiography or cardiology&#xD;
             consultation. These patients will require cardiology consultation and clearance prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  Congestive heart failure.&#xD;
&#xD;
          -  Chronic kidney disease, with creatinine clearance &lt; 60 ml/h.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus. Patients may be enrolled if they have been on stable&#xD;
             therapy with any anti-diabetic agent for at least 3 months prior to enrollment, are&#xD;
             not foreseen by the physician treating their diabetes to require antidiabetic&#xD;
             medication or dose changes during the trial and have an HbA1c &lt;= 7.5% on enrollment.&#xD;
&#xD;
          -  Treatment with vitamin E. Patients who are currently taking vitamin E as a supplement&#xD;
             will be requested to stop for at least 3 months before becoming eligible for&#xD;
             enrollment. Patients who are taking vitamin E for a medical indication other than&#xD;
             NAFLD will not be eligible.&#xD;
&#xD;
          -  Contraindication to or inability to undergo a liver biopsy.&#xD;
&#xD;
          -  Patients who had a liver biopsy performed &lt;= 2 years before enrollment, unless they&#xD;
             are willing to undergo all of the trial biopsies, knowing that these biopsies are&#xD;
             purely for research and are not clinically indicated. This will be clearly documented&#xD;
             in the patients charts prior to enrollment.&#xD;
&#xD;
          -  Patients with coagulopathy (PT/PTT values that are prolonged &gt;= 3 seconds from the&#xD;
             upper limit of the normal, including treatment with oral and parenteral&#xD;
             anticoagulants), thrombocytopenia (&lt;70,000), or platelet dysfunction will not be&#xD;
             enrolled because of potential increase in risk of bleeding with vitamin E treatment.&#xD;
             Antiplatelet agents taken for cardiovascular prevention will not exclude patients,&#xD;
             unless they cannot be stopped safely for the performance of a liver biopsy.&#xD;
&#xD;
          -  Maldigestion or malabsorption that can interfere with absorption of vitamin E&#xD;
             including: steatorrhea of all causes, chronic pancreatitis, cystic fibrosis, short&#xD;
             bowel syndrome, severe cholestasis, orlistat treatment and similar conditions&#xD;
&#xD;
          -  Inability to swallow vitamin E capsules&#xD;
&#xD;
          -  Allergy to vitamin E&#xD;
&#xD;
          -  Alcohol or substance abuse within the past 12 months. Patients will be required to&#xD;
             have an AUDIT score of 7 or less18, and drink no more than 14 drinks/week (for men) or&#xD;
             7 drinks/week (for women).&#xD;
&#xD;
          -  For women of childbearing age, pregnancy or inability (or unwillingness) to practice&#xD;
             contraception for the duration of the study or breast feeding.&#xD;
&#xD;
          -  Inability to understand and give informed consent for participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron Rotman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-DK-0002.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>March 5, 2020</verification_date>
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fatty Liver</keyword>
  <keyword>Alpha-Tocopherol</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Non-Alcoholic Steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT01792115/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vit E 200 IU/d</title>
          <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
        <group group_id="P2">
          <title>Vitamin E 400</title>
          <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
        <group group_id="P3">
          <title>Vitamin E 800</title>
          <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vit E 200 IU/d</title>
          <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
        <group group_id="B2">
          <title>Vitamin E 400</title>
          <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
        <group group_id="B3">
          <title>Vitamin E 800</title>
          <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="14.6"/>
                    <measurement group_id="B2" value="43.9" spread="9.3"/>
                    <measurement group_id="B3" value="48.4" spread="11.3"/>
                    <measurement group_id="B4" value="48.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Has Diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Diabetes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical: Number of Patients With Normal Transaminases at End of Treatment.</title>
        <description>Biochemical response defined as number of patients with normal transaminases AST &lt;=32 or ALT &lt;=35 U/L at end of treatment.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vit E 200 IU/d</title>
            <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E 400</title>
            <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O3">
            <title>Vitamin E 800</title>
            <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical: Number of Patients With Normal Transaminases at End of Treatment.</title>
          <description>Biochemical response defined as number of patients with normal transaminases AST &lt;=32 or ALT &lt;=35 U/L at end of treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physiological: Absolute Change in Liver Fat</title>
        <description>Physiological response defined as absolute change in liver fat measured by 1H-MRS</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vit E 200 IU/d</title>
            <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E 400</title>
            <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O3">
            <title>Vitamin E 800</title>
            <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Physiological: Absolute Change in Liver Fat</title>
          <description>Physiological response defined as absolute change in liver fat measured by 1H-MRS</description>
          <units>percent liver fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="9.6"/>
                    <measurement group_id="O2" value="-7.6" spread="3.3"/>
                    <measurement group_id="O3" value="-0.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in AST</title>
        <description>Absolute Change in AST [u/l] by week 24</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vit E 200 IU/d</title>
            <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E 400</title>
            <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O3">
            <title>Vitamin E 800</title>
            <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in AST</title>
          <description>Absolute Change in AST [u/l] by week 24</description>
          <units>u/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="11.1"/>
                    <measurement group_id="O2" value="-1.8" spread="4.5"/>
                    <measurement group_id="O3" value="-10.6" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in AST</title>
        <description>Percent change in AST by week 24</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vit E 200 IU/d</title>
            <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E 400</title>
            <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O3">
            <title>Vitamin E 800</title>
            <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in AST</title>
          <description>Percent change in AST by week 24</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.29"/>
                    <measurement group_id="O2" value="-0.07" spread="0.21"/>
                    <measurement group_id="O3" value="-0.24" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in ALT</title>
        <description>Absolute Change in ALT [u/l] by week 24</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vit E 200 IU/d</title>
            <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E 400</title>
            <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O3">
            <title>Vitamin E 800</title>
            <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in ALT</title>
          <description>Absolute Change in ALT [u/l] by week 24</description>
          <units>u/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8" spread="16.7"/>
                    <measurement group_id="O2" value="-8.3" spread="10.7"/>
                    <measurement group_id="O3" value="-22" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in ALT</title>
        <description>Percent change in ALT by week 24</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vit E 200 IU/d</title>
            <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E 400</title>
            <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O3">
            <title>Vitamin E 800</title>
            <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in ALT</title>
          <description>Percent change in ALT by week 24</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.44"/>
                    <measurement group_id="O2" value="-0.19" spread="0.23"/>
                    <measurement group_id="O3" value="-0.35" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in GGT</title>
        <description>Change in GGT by week 24 (U/L)</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vit E 200 IU/d</title>
            <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E 400</title>
            <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O3">
            <title>Vitamin E 800</title>
            <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in GGT</title>
          <description>Change in GGT by week 24 (U/L)</description>
          <units>u/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="24.5"/>
                    <measurement group_id="O2" value="-22.8" spread="50"/>
                    <measurement group_id="O3" value="-11" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Liver Fat</title>
        <description>Percent change in liver fat by week 24</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vit E 200 IU/d</title>
            <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E 400</title>
            <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
          <group group_id="O3">
            <title>Vitamin E 800</title>
            <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Liver Fat</title>
          <description>Percent change in liver fat by week 24</description>
          <units>percent of percent liver fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.93"/>
                    <measurement group_id="O2" value="-0.42" spread="0.18"/>
                    <measurement group_id="O3" value="-0.10" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data were collected over 144 weeks, from starting treatment to completion of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vit E 200 IU/d</title>
          <description>Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 200 IU/d: Supplement-low dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
        <group group_id="E2">
          <title>Vitamin E 400</title>
          <description>Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 400 IU/d: Supplement-intermediate dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
        <group group_id="E3">
          <title>Vitamin E 800</title>
          <description>Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.&#xD;
Vitamin E 800 IU/d: Supplement High Dose&#xD;
Diet and Exercise: Diet and Exercise for all Arms of the study at baseline</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis (medication non-compliance)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Bleed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diverticulitis with recto-vaginal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diuretic-induced hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency or anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Overt gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Herpes Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Jaw swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache/Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Galactorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Atelectasis (post-anesthesia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yaron Rotman</name_or_title>
      <organization>NIDDK</organization>
      <phone>301-451-6553</phone>
      <email>rotmanyaron@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

